Log in

NASDAQ:GERN - Geron Stock Price, Forecast & News

-0.05 (-4.46 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $1.07
50-Day Range
MA: $1.15
52-Week Range
Now: $1.07
Volume883,182 shs
Average Volume2.10 million shs
Market Capitalization$214.37 million
P/E RatioN/A
Dividend YieldN/A
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Read More
Geron logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GERN



Sales & Book Value

Annual Sales$460,000.00
Book Value$0.68 per share


Net Income$-68,550,000.00
Net Margins-14,901.74%


Market Cap$214.37 million
Next Earnings Date5/7/2020 (Estimated)

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Geron (NASDAQ:GERN) Frequently Asked Questions

How has Geron's stock been impacted by COVID-19 (Coronavirus)?

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 3.9% and is now trading at $1.07. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Geron?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its quarterly earnings results on Thursday, March, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. The biopharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $0.14 million. Geron had a negative return on equity of 44.66% and a negative net margin of 14,901.74%. During the same period last year, the company posted ($0.04) earnings per share. View Geron's earnings history.

What price target have analysts set for GERN?

4 analysts have issued 12-month price targets for Geron's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Geron's share price to reach $3.63 in the next year. This suggests a possible upside of 238.8% from the stock's current price. View analysts' price targets for Geron.

Has Geron been receiving favorable news coverage?

News stories about GERN stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next few days. View the latest news aboutGeron.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 69)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (1.82%), Geode Capital Management LLC (1.24%), Charles Schwab Investment Management Inc. (0.60%), Bank of America Corp DE (0.57%), Bank of New York Mellon Corp (0.41%) and Nuveen Asset Management LLC (0.35%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View institutional ownership trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, New York State Common Retirement Fund, Credit Suisse AG, UBS Asset Management Americas Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for Geron.

Which major investors are buying Geron stock?

GERN stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, California Public Employees Retirement System, Cambridge Investment Research Advisors Inc., Alpine Global Management LLC, Goldman Sachs Group Inc., State Street Corp, UBS Group AG, and Geode Capital Management LLC. View insider buying and selling activity for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.07.

How big of a company is Geron?

Geron has a market capitalization of $214.37 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 17 workers across the globe. View additional information about Geron.

What is Geron's official website?

The official website for Geron is http://www.geron.com/.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

MarketBeat Community Rating for Geron (NASDAQ GERN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  435 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  798
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel